When Hunger Is Biology, Not a Moral Failing

 By Dr. Marian Asaad

It did not take long for headlines to present BRP, a peptide identified by Stanford Medicine researchers with the help of artificial intelligence, as a possible natural rival to today’s best-known weight-loss drugs.

This is often how we respond to developments in obesity treatment. We either rush to celebrate a miracle cure or return to blaming patients for failing to eat less and exercise more.

Both responses miss the real significance of the discovery.

BRP, short for BRINP2-Related Peptide, is a naturally occurring molecule made up of just 12 amino acids. In early studies involving mice and miniature pigs, it reduced food intake, increased the time between meals and promoted fat loss while largely preserving lean body mass.

Researchers also reported no clear signs of food aversion, delayed stomach emptying or reduced activity in the animals studied.

These findings are encouraging, but they remain preclinical. BRP has not yet been tested in humans. We do not know the appropriate human dose, its long-term safety or whether the effects observed in animals will translate into meaningful and sustainable weight loss in people.

It is therefore premature to describe BRP as a replacement for GLP-1 medications, a “natural Ozempic” or a treatment free of adverse effects.

Scientific caution, however, should not lead us to overlook what this research is already telling us.

Its greatest value may not lie in the possibility of another injection for weight loss. It lies in reminding us that hunger is influenced by complex biological signals and that obesity cannot be reduced to a failure of personal discipline.

The researchers used artificial intelligence to examine thousands of human proteins in search of naturally produced molecules whose biological roles may have remained hidden. AI did not invent BRP, and it did not create a finished medicine. It helped scientists identify a signal that was already present within the human body but difficult to detect through conventional research methods.

That distinction matters.

If a peptide this small can influence appetite-regulating pathways in the brain, then hunger cannot honestly be described as nothing more than a decision to eat. Some people feel satisfied after a modest meal, while others continue to experience strong hunger signals despite having consumed enough energy. Some bodies respond to weight loss by intensifying appetite and reducing energy expenditure, effectively resisting the lower weight a person is trying to maintain.

These responses are not consciously chosen. People do not select their hormonal profile, their inherited biology or the way their brain responds to food cues.

Yet individuals living with obesity continue to hear the same advice: eat less, move more and show greater self-control.

Nutrition and physical activity are unquestionably important. But when these principles are used as accusations rather than components of care, they do not treat obesity. They deepen shame.

The problem with telling someone to “eat less” is not that the advice is entirely wrong. It is that it is painfully incomplete. It does not ask why one person experiences stronger hunger than another, why fullness is difficult to achieve, why weight often returns after months of restriction or how sleep deprivation, medication, stress, hormonal changes and the surrounding food environment may be influencing the body.

The discovery of BRP offers another reminder that appetite is regulated by biology, not governed by character alone.

Medications such as semaglutide and tirzepatide have already changed the treatment of obesity by showing that medically reducing appetite can help patients achieve outcomes that lifestyle advice alone did not make possible.

Their success does not mean they are suitable for everyone. Some patients experience significant gastrointestinal symptoms. Others cannot afford to continue treatment or have difficulty accessing it consistently. Many regain some weight after stopping the medication.

BRP has attracted interest because early evidence suggests that it acts through a pathway different from the mechanisms targeted by current GLP-1-based therapies. It may eventually offer an option for patients who cannot tolerate existing medications, or it may be used alongside other treatments.

For now, those are possibilities rather than clinical facts.

My concern is that enthusiasm surrounding BRP may soon be used to market unregulated peptides, injections or supplements online under appealing phrases such as “natural,” “AI-discovered” or “free from side effects.”

A substance does not automatically become safe simply because it occurs naturally in the body. Insulin and hormones are natural biological substances, yet using them medically requires precise dosing, reliable manufacturing, careful monitoring and professional supervision.

Products sold online as “research peptides” may contain incorrect concentrations, contaminants or substances entirely different from those listed on the label.

A patient’s hope should never become someone else’s commercial opportunity.

From a nutritional perspective, treatments that reduce appetite do not make food less important. They make the quality of food more important.

When a person eats substantially less, ensuring an adequate intake of protein, fibre, vitamins, minerals and fluids becomes essential. Weight may fall while the patient also loses muscle, becomes physically weaker or develops nutritional deficiencies.

Success cannot mean weight loss at any cost.

Good obesity treatment should not prevent a person from eating. It should help reduce the constant biological struggle with hunger while allowing the body to receive the nourishment it needs.

Medication also cannot address every reason a person eats. It cannot, by itself, resolve emotional eating linked to loneliness, anxiety, trauma or chronic stress. It cannot restore healthy sleep or change an environment in which highly processed, calorie-dense foods are inexpensive, convenient and aggressively promoted.

This is why nutritional care, appropriate movement and psychological support remain central to responsible obesity treatment.

We should stop presenting medication and nutrition as opposing choices.

One person may improve through dietary changes and physical activity. Another may need medication. A third may benefit from bariatric surgery or a combination of medical, nutritional and psychological care.

These are not moral categories in which one person succeeds through virtue while another fails through weakness. They are different clinical situations requiring different forms of treatment.

Artificial intelligence has shown what it can contribute when it is used as a research tool rather than marketed as a machine for producing medical miracles. It helped scientists find a promising molecule, but it cannot yet tell us whether BRP will be safe, effective or sustainable in human patients.

Those answers still depend on the slower and less glamorous work of medicine: toxicity studies, carefully designed clinical trials, independent review, repeated testing and the willingness to accept disappointing results when evidence demands it.

BRP may one day become an important obesity treatment. It may also fail before reaching clinical practice.

Either outcome is possible.

What the discovery has already given us is another reason to reconsider the way we speak about hunger and weight.

A person living with obesity does not need another lecture on willpower. They need a physician who understands the complexity of the condition, a nutrition professional who does not punish them with endless lists of forbidden foods and a society that does not confuse body size with human worth.

Perhaps the most valuable promise of BRP, at least for now, is not the possibility of a thinner body.

It is the possibility of a fairer and more compassionate understanding of the person living inside it.

Residents of 70 Mile House and surrounding areas in British Columbia are preparing for an evacuation order after two major wildfires merged in the South Cariboo region, creating a fire estimated at nearly 668 square kilometres.

The Thompson-Nicola Regional District, or TNRD, said its emergency operations centre, in coordination with the BC Wildfire Service, planned to issue an evacuation order at 10 a.m. Pacific Time on Monday, July 27, because of the projected growth of the Pear Lake wildfire toward the community.

Officials urged residents to prepare to leave by gathering identification documents, medications, clothing and other essential supplies. People in the affected area were advised to follow local instructions immediately once the evacuation order takes effect.

As of the latest published official update, 70 Mile House and several surrounding areas were listed under an evacuation alert, meaning residents must be ready to leave on short notice. Several nearby areas were already subject to mandatory evacuation orders.

The Pear Lake wildfire, which now includes the former Fiftynine Creek fire, was mapped at approximately 66,871 hectares, equivalent to about 668.7 square kilometres. The two fires merged near Chasm, approximately 12 kilometres north of Clinton, and the fire also affected sections of Highway 97.

The Village of Clinton and neighbouring areas had already been ordered to evacuate as the fire continued to burn aggressively and authorities expanded evacuation zones across the region.

The BC Wildfire Service said cooler temperatures could provide crews with a limited reprieve, but strong winds and underlying drought conditions were expected to remain significant factors in fire behaviour. Further growth and increased smoke were also anticipated, particularly during the afternoon and evening.

The planned evacuation order was not expected to include South Green Lake, which was set to remain under an evacuation alert. Emergency Support Services were expected to become available after the order took effect, providing temporary help with accommodation, food and other basic needs.

Authorities urged residents to continue monitoring official emergency maps and updates from the Thompson-Nicola Regional District and the BC Wildfire Service, and to avoid entering evacuated areas unless officials confirm it is safe.

By Dr. Marian Asaad

It did not take long for headlines to present BRP, a peptide identified by Stanford Medicine researchers with the help of artificial intelligence, as a possible natural rival to today’s best-known weight-loss drugs.

This is often how we respond to developments in obesity treatment. We either rush to celebrate a miracle cure or return to blaming patients for failing to eat less and exercise more.

Both responses miss the real significance of the discovery.

BRP, short for BRINP2-Related Peptide, is a naturally occurring molecule made up of just 12 amino acids. In early studies involving mice and miniature pigs, it reduced food intake, increased the time between meals and promoted fat loss while largely preserving lean body mass. Researchers also reported no clear signs of food aversion, delayed stomach emptying or reduced activity in the animals studied.

These findings are encouraging, but they remain preclinical. BRP has not yet been tested in humans. We do not know the appropriate human dose, its long-term safety or whether the effects observed in animals will translate into meaningful and sustainable weight loss in people.

It is therefore premature to describe BRP as a replacement for GLP-1 medications, a “natural Ozempic” or a treatment free of adverse effects.

Scientific caution, however, should not lead us to overlook what this research is already telling us.

Its greatest value may not lie in the possibility of another injection for weight loss. It lies in reminding us that hunger is influenced by complex biological signals and that obesity cannot be reduced to a failure of personal discipline.

The researchers used artificial intelligence to examine thousands of human proteins in search of naturally produced molecules whose biological roles may have remained hidden. AI did not invent BRP, and it did not create a finished medicine. It helped scientists identify a signal that was already present within the human body but difficult to detect through conventional research methods.

That distinction matters.

If a peptide this small can influence appetite-regulating pathways in the brain, then hunger cannot honestly be described as nothing more than a decision to eat. Some people feel satisfied after a modest meal, while others continue to experience strong hunger signals despite having consumed enough energy. Some bodies respond to weight loss by intensifying appetite and reducing energy expenditure, effectively resisting the lower weight a person is trying to maintain.

These responses are not consciously chosen. People do not select their hormonal profile, their inherited biology or the way their brain responds to food cues.

Yet individuals living with obesity continue to hear the same advice: eat less, move more and show greater self-control.

Nutrition and physical activity are unquestionably important. But when these principles are used as accusations rather than components of care, they do not treat obesity. They deepen shame.

The problem with telling someone to “eat less” is not that the advice is entirely wrong. It is that it is painfully incomplete. It does not ask why one person experiences stronger hunger than another, why fullness is difficult to achieve, why weight often returns after months of restriction or how sleep deprivation, medication, stress, hormonal changes and the surrounding food environment may be influencing the body.

The discovery of BRP offers another reminder that appetite is regulated by biology, not governed by character alone.

Medications such as semaglutide and tirzepatide have already changed the treatment of obesity by showing that medically reducing appetite can help patients achieve outcomes that lifestyle advice alone did not make possible.

Their success does not mean they are suitable for everyone. Some patients experience significant gastrointestinal symptoms. Others cannot afford to continue treatment or have difficulty accessing it consistently. Many regain some weight after stopping the medication.

BRP has attracted interest because early evidence suggests that it acts through a pathway different from the mechanisms targeted by current GLP-1-based therapies. It may eventually offer an option for patients who cannot tolerate existing medications, or it may be used alongside other treatments.

For now, those are possibilities rather than clinical facts.

My concern is that enthusiasm surrounding BRP may soon be used to market unregulated peptides, injections or supplements online under appealing phrases such as “natural,” “AI-discovered” or “free from side effects.”

A substance does not automatically become safe simply because it occurs naturally in the body. Insulin and hormones are natural biological substances, yet using them medically requires precise dosing, reliable manufacturing, careful monitoring and professional supervision.

Products sold online as “research peptides” may contain incorrect concentrations, contaminants or substances entirely different from those listed on the label.

A patient’s hope should never become someone else’s commercial opportunity.

From a nutritional perspective, treatments that reduce appetite do not make food less important. They make the quality of food more important.

When a person eats substantially less, ensuring an adequate intake of protein, fibre, vitamins, minerals and fluids becomes essential. Weight may fall while the patient also loses muscle, becomes physically weaker or develops nutritional deficiencies.

Success cannot mean weight loss at any cost.

Good obesity treatment should not prevent a person from eating. It should help reduce the constant biological struggle with hunger while allowing the body to receive the nourishment it needs.

Medication also cannot address every reason a person eats. It cannot, by itself, resolve emotional eating linked to loneliness, anxiety, trauma or chronic stress. It cannot restore healthy sleep or change an environment in which highly processed, calorie-dense foods are inexpensive, convenient and aggressively promoted.

This is why nutritional care, appropriate movement and psychological support remain central to responsible obesity treatment.

We should stop presenting medication and nutrition as opposing choices.

One person may improve through dietary changes and physical activity. Another may need medication. A third may benefit from bariatric surgery or a combination of medical, nutritional and psychological care.

These are not moral categories in which one person succeeds through virtue while another fails through weakness. They are different clinical situations requiring different forms of treatment.

Artificial intelligence has shown what it can contribute when it is used as a research tool rather than marketed as a machine for producing medical miracles. It helped scientists find a promising molecule, but it cannot yet tell us whether BRP will be safe, effective or sustainable in human patients.

Those answers still depend on the slower and less glamorous work of medicine: toxicity studies, carefully designed clinical trials, independent review, repeated testing and the willingness to accept disappointing results when evidence demands it.

BRP may one day become an important obesity treatment. It may also fail before reaching clinical practice.

Either outcome is possible.

What the discovery has already given us is another reason to reconsider the way we speak about hunger and weight.

A person living with obesity does not need another lecture on willpower. They need a physician who understands the complexity of the condition, a nutrition professional who does not punish them with endless lists of forbidden foods and a society that does not confuse body size with human worth.

Perhaps the most valuable promise of BRP, at least for now, is not the possibility of a thinner body.

It is the possibility of a fairer and more compassionate understanding of the person living inside it.